PAREXEL Opens Shenyang Office to Support Business Growth in Asia
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that the Company has opened a new office in Shenyang, China. This location will support growing client demand for a broad range of clinical development capabilities in the country and throughout the Asia Pacific region. The office further expands PAREXEL’s presence in China which includes locations in Beijing, Chengdu, Guangzhou, Shanghai and Hong Kong. PAREXEL now has 22 offices throughout important biopharmaceutical centers in the Asia Pacific region, which in addition to China, includes a presence in Australia, Japan, India, Indonesia, Malaysia, the Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam.
“Given the globalization of clinical trials today and the continuing shift of drug development activity from West to East, China has become an important strategic destination for PAREXEL’s clients and business,” said Mark Goldberg, PAREXEL’s President and COO. “With the opening of the Shenyang operation hub in China, PAREXEL commits to continuing to expand its service scope and local expertise. The office also further reinforces our social investment in the region through a collaboration with Shenyang Pharmaceutical University to train graduates on clinical trial conduct, data management and pharmacovigilance knowledge.”
The Shenyang office will also enable the Company to bring Perceptive eClinical technology solutions to the Asia Pacific market. Built on the leading-edge PAREXEL MyTrials™ platform and combined with PAREXEL’s extensive medical and clinical expertise, clinical trial sponsors are able to more efficiently manage the clinical development process from study design to data collection and ultimately, to regulatory submission.
As part of the initiative, PAREXEL Academy will offer graduates and alumni of Shenyang Pharmaceutical University’s School of Life Science and Biopharmaceuticals opportunities to work alongside PAREXEL staff who are involved in regional and global clinical studies. This offering is in addition to the abundant full-time PAREXEL career opportunities already available to the same graduates and alumni.
“We are pleased to have the opportunity to collaborate with PAREXEL, one of the CRO industry leaders,” said Professor Jing-Yu Yang, Dean of Shenyang Pharmaceutical University. “The collaboration will not only provide our Clinical Pharmacy students with the opportunity to learn about new drug development, but it will also create a foundation for research and cultivation of the next generation of talent.”
A ceremony to mark the official opening of PAREXEL’s Shenyang operations will take place on Thursday, May 16.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
